- Treatment modalities and outcomes by mycosis fungoides stage.
| Characteristics | Stages | All | |||||
|---|---|---|---|---|---|---|---|
| IA | IB | IIA | IIB | III | IVB | ||
| Treatment modality | |||||||
| Topical corticosteroids | 25 (43.1) | 22 (37.9) | 2 (3.4) | 1 (1.7) | 7 (12.1) | 1 (1.7) | 58 (100) |
| NBUVB | 21 (45.7) | 15 (32.6) | 1 (2.2) | 1 (2.2) | 7 (15.2) | 1 (2.2) | 46 (100) |
| PUVA | 3 (50.0) | 0 (0.0) | 1 (16.7) | 0 (0.0) | 0 (0.0) | 2 (33.3) | 6 (100) |
| Radiation therapy | 2 (28.6) | 1 (14.3) | 1 (14.3) | 1 (14.3) | 1 (14.3) | 1 (14.3) | 7 (100) |
| Chemotherapy | 0 (0.0) | 2 (22.2) | 1 (11.1) | 0 (0.0) | 4 (44.4) | 2 (22.2) | 9 (100) |
| Topical chlormethine | 2 (33.3) | 2 (33.3) | 0 (0.0) | 0 (0.0) | 1 (16.7) | 1 (16.7) | 6 (100) |
| Duration of treatment (months), mean (range) | 34 (3-168) | 26 (1-168) | 14 (4-31) | 72 (72-72) | 34 (3-74) | 24 (5-48) | 31 (1-168) |
| Duration of follow-up (months), mean (range) | 34 (1-108) | 32 (1-72) | 19 (0-48) | 72 (72-72) | 49 (3-144) | 32 (12-48) | 35 (0-144) |
| Outcomes | |||||||
| Complete remission | 7 (63.6) | 3 (27.3) | 1 (9.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 11 (100) |
| Partial response | 6 (31.6) | 8 (42.1) | 0 (0.0) | 1 (5.3) | 2 (10.5) | 2 (10.5) | 19 (100) |
| Stable disease | 16 (53.3) | 9 (30.0) | 2 (6.7) | 0 (0.0) | 3 (10.0) | 0 (0.0) | 30 (100) |
| Progressive disease | 3 (30.0) | 3 (30.0) | 0 (0.0) | 0 (0.0) | 3 (30.0) | 1 (10.0) | 10 (100) |
| Relapse | 2 (66.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (33.3) | 0 (0.0) | 3 (100) |
| Mortality | |||||||
| Deceased | 0 (0.0) | 0 (0.0) | 1 (33.3) | 0 (0.0) | 0 (0.0) | 2 (66.7) | 3 (100) |
NBUVB: narrow-band ultraviolet B, PUVA: psoralen plus ultraviolet-A